GLP-1 Titration Protocols: Clinical Dose Escalation Guide for Providers
Evidence-based titration protocols for semaglutide, tirzepatide, and retatrutide. Standard schedules, modified protocols for sensitive patients, and managing dose-limiting side effects.
More on Provider-Facing
Clinical Reference
Standardized titration protocols for GLP-1 agonists including standard and modified (sensitive patient) schedules. Slow titration reduces discontinuation rates by approximately 40% compared to accelerated schedules.
Titration Schedules
Semaglutide Standard
Total time to maximum dose: 16 weeks to max
Semaglutide Modified (Sensitive)
Total time to maximum dose: 32 weeks to max
Tirzepatide Standard
Total time to maximum dose: 20 weeks to max
Tirzepatide Modified (Sensitive)
Total time to maximum dose: 40 weeks to max
Dose Escalation Decision Points
Proceed to Next Dose When
- GI side effects resolved or manageable
- Minimum 4 weeks at current dose completed
- Appetite returning between doses
- Weight loss rate slowing at current dose
Hold or Reduce Dose When
- Persistent vomiting beyond 2 weeks at dose
- Dehydration signs despite adequate intake efforts
- Weight loss exceeding 1 kg/week consistently
- Elevated lipase/amylase (3x ULN)
Special Population Considerations
Elderly Patients (65+)
Use modified (slower) titration. Monitor renal function more frequently. Emphasize protein intake to prevent sarcopenia. Be vigilant for dehydration. Consider lower maximum dose targets. Monitor for falls risk from orthostatic changes.
Patients with Renal Impairment
No dose adjustment required for semaglutide or tirzepatide based on renal function. However, GI side effects increasing dehydration risk can worsen renal function. Monitor eGFR every 3 months. Extra caution with concurrent nephrotoxic medications.
Patients on Insulin or Sulfonylureas
Proactively reduce insulin doses by 20-30% when initiating GLP-1 therapy. Consider halving sulfonylurea doses. Monitor blood glucose closely during titration. Hypoglycemia risk is the primary concern. Adjust diabetes medications as weight loss improves glycemic control.
Clinical Disclaimer: This guide is for licensed healthcare providers. Verify current prescribing information. Individual patient assessment supersedes protocol guidelines. Trimi providers are available for clinical consultation.
Frequently Asked Questions
What is the standard semaglutide titration schedule?
Standard protocol: 0.25mg x 4 weeks, 0.5mg x 4 weeks, 1.0mg x 4 weeks, 1.7mg x 4 weeks, then 2.4mg maintenance. Each step is minimum 4 weeks. Extended stays at any dose are appropriate for GI tolerability. Not all patients require the maximum dose.
When should I use a modified (slower) titration?
Consider slower titration for: elderly patients, patients with gastroparesis history, those on medications affecting GI motility, patients with high nausea sensitivity, and those with prior GLP-1 intolerance. Modified protocol doubles the time at each dose level to 8 weeks.
What indicates a patient has reached their optimal dose?
Optimal dose criteria: adequate appetite suppression, tolerable side effects, satisfactory weight loss trajectory (minimum 1% per month), patient comfort and adherence. The optimal dose is not necessarily the maximum dose -- many patients achieve excellent results at intermediate doses.
How should I manage dose-limiting side effects?
If side effects prevent dose escalation: maintain current dose for additional 4-8 weeks, optimize anti-emetic support, ensure adequate hydration, consider splitting injection technique (half doses twice weekly off-label), or accept current dose as the patient's therapeutic maximum.
Refer Patients to Trimi
Compounded semaglutide from $99/mo or tirzepatide from $125/mo with full clinical oversight.
View Treatment OptionsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).